Lysosomal storage disorders (LSDs) are inherited rare diseases caused by the lack or malfunction of proteins involved in lysosomal activity. Enzyme replacement therapies (ERTs, based on the administration of a functional version of the defective enzyme) have gained clinical relevance in LSD health care. Therefore, production of therapeutic enzymes is a key aspect in the development of therapies for many rare diseases.